Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
See the World with Dollar Flight Club's Lowest Price for Black Friday Weekend
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
On outskirts of Doha, laborers watch World Cup they built
THE BEST BLACK FRIDAY DEAL YET (Ad)
Biden eases Venezuela sanctions as opposition talks resume
Whole Foods decision to pull lobster divides enviros, pols
THE BEST BLACK FRIDAY DEAL YET (Ad)
NASDAQ:PRTA

Prothena - PRTA Stock Forecast, Price & News

$61.28
-0.67 (-1.08%)
(As of 11/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$61.01
$62.28
50-Day Range
$29.01
$63.45
52-Week Range
$21.06
$65.35
Volume
66,075 shs
Average Volume
533,694 shs
Market Capitalization
$2.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.40

Prothena MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
27.9% Upside
$78.40 Price Target
Short Interest
Healthy
5.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Prothena in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$9.89 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.87) to ($3.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

402nd out of 1,044 stocks

Pharmaceutical Preparations Industry

191st out of 510 stocks

PRTA stock logo

About Prothena (NASDAQ:PRTA) Stock

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Stock News Headlines

Prothena Third Quarter 2022 Earnings: Misses Expectations
Prothena Corporation PLC
Midday Movers: Biogen, Apple, DocuSign and More
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Company Calendar

Last Earnings
11/04/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/16/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTA
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$78.40
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+27.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$66.97 million
Net Margins
-3,036.03%
Pretax Margin
-3,144.08%

Debt

Sales & Book Value

Annual Sales
$200.58 million
Cash Flow
$1.57 per share
Book Value
$8.36 per share

Miscellaneous

Free Float
33,283,000
Market Cap
$2.96 billion
Optionable
Optionable
Beta
0.48

Key Executives

  • Dr. Gene G. Kinney Ph.D.Dr. Gene G. Kinney Ph.D. (Age 53)
    Pres, CEO & Director
    Comp: $1.02M
  • Mr. Tran B. Nguyen M.B.A.Mr. Tran B. Nguyen M.B.A. (Age 48)
    CFO & Chief Strategy Officer
    Comp: $745.35k
  • Mr. Brandon S. Smith (Age 47)
    Chief Operating Officer
    Comp: $648.34k
  • Ms. Carol D. KarpMs. Carol D. Karp (Age 69)
    Chief Regulatory Officer
    Comp: $679.3k
  • Dr. Hideki Garren M.D. (Age 57)
    Ph.D., Chief Medical Officer
    Comp: $859.64k
  • Ms. Karin L. Walker CPAMs. Karin L. Walker CPA (Age 59)
    CPA, Chief Accounting Officer & Controller
  • Dr. Wagner M. ZagoDr. Wagner M. Zago (Age 49)
    Chief Scientific Officer
  • Ms. Jennifer Zibuda
    Director of Investor Relations & Communication
  • Mr. Michael J. MalecekMr. Michael J. Malecek (Age 56)
    Chief Legal Officer
  • Ms. Yvonne M. Tchrakian
    Company Sec.













PRTA Stock - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price forecast for 2023?

5 brokers have issued 12-month target prices for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $120.00. On average, they expect the company's stock price to reach $78.40 in the next twelve months. This suggests a possible upside of 27.9% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2022?

Prothena's stock was trading at $49.40 on January 1st, 2022. Since then, PRTA shares have increased by 24.0% and is now trading at $61.28.
View the best growth stocks for 2022 here
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) issued its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported $2.13 earnings per share for the quarter, missing the consensus estimate of $2.25 by $0.12. The biotechnology company earned $139.17 million during the quarter, compared to the consensus estimate of $140.08 million. Prothena had a negative net margin of 3,036.03% and a negative trailing twelve-month return on equity of 36.46%. During the same period last year, the company posted ($0.77) EPS.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.49%), Price T Rowe Associates Inc. MD (6.16%), State Street Corp (3.89%), Palo Alto Investors LP (3.41%), First Light Asset Management LLC (3.18%) and Dimensional Fund Advisors LP (3.07%). Insiders that own company stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $61.28.

How much money does Prothena make?

Prothena (NASDAQ:PRTA) has a market capitalization of $2.96 billion and generates $200.58 million in revenue each year. The biotechnology company earns $66.97 million in net income (profit) each year or ($3.34) on an earnings per share basis.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510.

This page (NASDAQ:PRTA) was last updated on 11/27/2022 by MarketBeat.com Staff